Dr. John L. Kulp III has a Ph.D. in Chemistry from New York University. Dr. Kulp’s background is in the field of bioorganic chemistry with specialization in (i) protein nuclear magnetic resonance (NMR) structure determination, (ii) computational methods for studying protein structure, (iii) synthetic peptide chemistry, and (iv), most recently, computational fragment-based drug design. During his postdoctoral training at the Naval Research Laboratory, he developed peptide nanopores as stochastic sensing elements and patented a new class of β-helical peptide architectures. After completing his postdoctoral fellowship, he was hired as a federal staff scientist where he helped develop a program to study biointerfaces. Dr. Kulp chose to leave the Navy and follow his research interests in therapeutic discovery. In 2010, Dr. Kulp joined BioLeap, a small business that specializes in protein-protein interactions and that has a proprietary fragment-based computational chemistry software platform. He has participated in development of novel inhibitors for DHFR, PCSK9, 11β-HSD, and recA. He is currently researching the modularity of natural products from a fragment-based approach. Fragment generation from natural products provides key insights into way in which we might harness Nature’s generalized synthesis platforms for novel compounds. Using natural product derived fragment maps exposes where, and how, we might alter biosynthetic pathways or where to modify existing natural products using medicinal chemistry.

John l. Kulp III, ph. d.